WuXi Biologics (2269.HK), a global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announced yesterday its strategic collaboration with Brii Biosciences, a biotechnology company that operates in China and the US, focusing on accelerating innovation and optimising access to serve the need of Chinese patients and public health.
The collaboration is aimed at discovering and developing bispecific antibodies to treat infectious diseases and other immunologic disorders. It is intended to further integrate the advantages of both firms and to accelerate the development of Brii Bio's pipeline. According to the terms of the contract, Brii Bio has access to WuXi Biologics' entire antibody platform capabilities including the WuXiBody technology to discover novel bispecific antibodies. WuXi Biologics will also be the exclusive development and manufacturing partner of any novel bispecific antibodies discovered from the WuXiBody Platform.
Dr Zhi Hong, co-founder and chief executive officer of Brii Biosciences, said, 'Discovery of novel immunotherapeutics modulating the host immune responses represents an untapped paradigm that may improve the treatment of infectious diseases. WuXi Biologics has successfully grown and expanded its capability and capacity in biopharmaceutical, which will enable us to translate target insight to key therapeutic modalities and innovate in China for the world.'
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer